RESUMO
Corneal neovascularization is a serious condition that may arise secondary to chemical burns, ischemia, infection, trauma, and inflammation and represents a major cause of blindness. This study investigated the efficacy of topical application of infliximab [tumor necrosis factor-a (TNF-a) monoclonal antibody] in the treatment of corneal neovascularization in the rabbit model.
Assuntos
Neovascularização da Córnea/tratamento farmacológico , Infliximab/uso terapêutico , Soluções Oftálmicas/uso terapêutico , Álcalis/química , Inibidores da Angiogênese/uso terapêutico , Animais , Anticorpos Monoclonais/uso terapêutico , Neovascularização da Córnea/patologia , CoelhosRESUMO
Corneal avascularity is necessary for the preservation of optimal vision. The cornea maintains a dynamic balance between pro- and antiangiogenic factors that allows it to remain avascular under normal homeostatic conditions. Corneal neovascularization (NV) is a condition that can develop in response to inflammation, hypoxia, trauma, or limbal stem cell deficiency and it is a significant cause of blindness. New therapeutic options for diseases of the cornea and ocular surface are now being explored in experimental animals and clinical trials. Antibody based biologics are being tested for their ability to reduce blood and lymphatic vessel ingrowth into the cornea, and to reduce inflammation. Numerous studies have shown that biologics with specificity for VEGF A such as bevacizumab and ranibizumab (a recombinant antibody and an antibody fragment, respectively) or anti-tumor necrosis factor-α microantibody, are effective in the treatment of corneal neovascularization.